In this study, the patients were allocated to receive two doses on the anti-PD1 antibody nivolumab about 4 weeks before resection of stage I, II or IIIA NSCLC: the immunotherapy treatment did not delay surgery and of the 21 primary tumors removed, 20 were completely resected [310]. Here, PDCD1 is linked to non-small cell lung carcinoma.